Evidence map›Paper›PMID 35244769›Full record

ArticleJournal of gastroenterology2022

Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.

Wansong Lin, Jie Lin, Jieyu Li, Ying Lin, Shuping Chen, Yijuan Wu, Lingfeng Chen, Hui Cheng, Lin Liu, Xiaoyan Chen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wansong Lin *Laboratory of Immuno-Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No.420, Fuma Road, Jinan District, Fuzhou, 350014, Fujian, China.
Jie Lin *Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China. sllinjie@163.com.ORCID 0000-0002-9741-575X
Jieyu LiLaboratory of Immuno-Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No.420, Fuma Road, Jinan District, Fuzhou, 350014, Fujian, China.
Ying LinDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Shuping ChenLaboratory of Immuno-Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No.420, Fuma Road, Jinan District, Fuzhou, 350014, Fujian, China.
Yijuan WuDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Lingfeng ChenDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Hui ChengDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Lin LiuDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Xiaoyan ChenDepartment of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, No.134, Dong Street, Gulou District, Fuzhou, 350001, Fujian, China.
Yunbin YeLaboratory of Immuno-Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No.420, Fuma Road, Jinan District, Fuzhou, 350014, Fujian, China. yeyb@fjzlhospital.com.
Fujian Medical University · CN

Funding

Joint Funds for the innovation of Science and Technology, Fujian province 2018Y9104Joint Funds for the innovation of Science and Technology, Fujian province 2018Y9108National Natural Science Foundation of China 81802882Natural Science Foundation of Fujian Province 2018J01251
6 · The paper itself

Abstract

backgroundUpregulated Kindlin-2 expression in hepatocellular carcinoma (HCC) correlates with metastasis and poor prognosis. In this study, we investigated the molecular mechanism of Kindlin-2 in HCC.

methodsKindlin-2 downstream pathways were explored through microRNA sequencing. The Kindlin-2-miR-1258-TCF4 axis was verified using bisulfite sequencing, a luciferase reporter assay, quantitative real-time PCR, and rescue assays. Binding of TCF4 to the Kindlin-2 promoter was confirmed by promoter activity analysis and chromatin immunoprecipitation.

resultsMiRNA sequencing identified miR-1258 as a downstream effector of Kindlin-2. MiR-1258 expression was increased following Kindlin-2 knockdown and decreased after Kindlin-2 overexpression. Next, we identified transcription factor 7 like 2 (TCF7L2 or TCF4) as a target of miR-1258 and found that Kindlin-2 upregulated TCF4 expression by epigenetically suppressing miR-1258 in HCC. Furthermore, our results suggest that TCF4 binds to the Kindlin-2 promotor to enhance its transcription. Therefore, Kindlin-2-miR-1258-TCF4 interaction creates a positive feedback loop. Functional assays and animal experiments demonstrated critical roles of miR-1258 and TCF4 in HCC cell migration in vitro and HCC metastasis in vivo. In HCC tissues, Kindlin-2 expression correlated negatively with miR-1258 expression and positively with TCF4 expression. Meanwhile, miR-1258 expression correlated negatively with TCF4 expression.

conclusionsThis study illustrates a novel integrin-independent signaling pathway, Kindlin-2-miR-1258-TCF4, that regulates HCC invasion and metastasis and identifies Kindlin-2 as a promising therapeutic target in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMembrane ProteinsMicroRNAsNeoplasm ProteinsTranscription Factor 4AnimalsCell Line, TumorCell MovementCell ProliferationFeedbackFeedback, SensoryHumansNeoplasm MetastasisFERMT2 protein, humanMembrane ProteinsMicroRNAsMIRN1258 microRNA, humanNeoplasm ProteinsTCF4 protein, humanTranscription Factor 4Hepatocellular carcinomaKindlin-2MetastasismicroRNA-1258TCF4

Identifiers

PMID35244769
OpenAlexW4214874447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.